DJI45,577.47-0.96%
GDAXI22,380.19-2.01%
GSPC6,506.48-1.51%
HSI25,277.32-0.88%
IXIC21,647.61-2.01%
N22550,777.45-4.86%
AAPL247.99-0.39%
AMZN205.37-1.63%
CL98.51+0.29%
EURUSD1.1561-0.12%
GBPUSD1.3333-0.09%
GC4,360.80-4.68%
GOOG298.79-2.27%
JPM286.56-0.49%
META593.66-2.15%
MSFT381.85-1.85%
NVDA172.93-3.03%
TSLA367.96-3.24%
DJI45,577.47-0.96%
GDAXI22,380.19-2.01%
GSPC6,506.48-1.51%
HSI25,277.32-0.88%
IXIC21,647.61-2.01%
N22550,777.45-4.86%
AAPL247.99-0.39%
AMZN205.37-1.63%
CL98.51+0.29%
EURUSD1.1561-0.12%
GBPUSD1.3333-0.09%
GC4,360.80-4.68%
GOOG298.79-2.27%
JPM286.56-0.49%
META593.66-2.15%
MSFT381.85-1.85%
NVDA172.93-3.03%
TSLA367.96-3.24%
DJI45,577.47-0.96%
GDAXI22,380.19-2.01%
GSPC6,506.48-1.51%
HSI25,277.32-0.88%
IXIC21,647.61-2.01%
N22550,777.45-4.86%
AAPL247.99-0.39%
AMZN205.37-1.63%
CL98.51+0.29%
EURUSD1.1561-0.12%
GBPUSD1.3333-0.09%
GC4,360.80-4.68%
GOOG298.79-2.27%
JPM286.56-0.49%
META593.66-2.15%
MSFT381.85-1.85%
NVDA172.93-3.03%
TSLA367.96-3.24%
LIVE
USA Yahoo Finance EN

Collegium Pharmaceutical to Buy AZSTARYS for $650M, Expanding ADHD Franchise Through 2037

Mar 19, 2026 &03511919202631; 13:51 UTC finance.yahoo.com
Read original on finance.yahoo.com ↗
Neutral impact
Sentiment score: +20/100
Low impact Short-term (days)
WHAT THIS MEANS
Collegium Pharmaceutical's acquisition of AZSTARYS for $650 million aims to expand its ADHD treatment portfolio, potentially boosting long-term revenue streams through 2037 by leveraging the drug's market presence. However, the deal's success depends on integration challenges and regulatory approvals, which could limit immediate financial benefits. Overall, this may enhance Collegium's competitive edge in the pharmaceutical sector but is unlikely to significantly impact broader markets without additional catalysts.
AI CONFIDENCE
60% High
SENTIMENT GAUGE
NEWS POWER SCORE
AFFECTED ASSETS
S&P 500
^GSPCIndex
High volatility expected
The acquisition could introduce minor volatility in the S&P 500 due to US pharma sector activity, but the market may have already anticipated such deals, limiting upside potential amid broader economic uncertainties.
Euro Stoxx 50
^STOXX50EIndex
Uncertain
As a US-based deal, it has minimal direct impact on European indices, though any global pharma trends might indirectly cause slight fluctuations.
PRICE HISTORY
Loading chart...
SUGGESTED ACTION
Consider holding or monitoring Collegium-related assets for short-term price movements, but avoid aggressive trades in broader indices until more details on the acquisition's financial outcomes emerge, as macro headwinds like inflation could overshadow this event.
KEY SIGNALS
Pharmaceutical M&A activityExpansion in ADHD market
SECTORS INVOLVED
Healthcare
Analysis generated on Mar 22, 2026 at 23:00 UTC
Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Yahoo Finance. Always conduct your own research and consult a qualified financial advisor before making investment decisions.